No difference in event-free survival (EFS) was observed in children and adolescents with newly diagnosed Hodgkin lymphoma (HL) according to race/ethnicity; however, postrelapse mortality was found to be higher in nonwhite groups. The findings from this pooled, secondary analysis of data from phase 3 clinical trials of dose-dense, response-adapted therapy were published in the Journal…
Agreement between patient- and physician-reported adverse effects during phase 1 clinical trials varies from poor to fair.
Researchers identify trends in use of complementary medicine among patients with breast, colorectal, or lung cancer while participating in phase 3 clinical trials.
Researchers demonstrated the significance of access to supportive and posttrial care as it relates to cancer survival among clinical trial participants.
Draft guidance that men be included in breast cancer trials issued by the FDA.